Clinical trial
Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C…
NCT00439959 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00439959 |
|---|---|
| Title | Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults |
| Official title | A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK625433 in Healthy Subjects and in Subjects Who Are Chronically Infected With Hepatitis C. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | GSK625433/placebo |
| Enrollment | 48 |
| Start date | Oct 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Feb 26, 2007 |
| Last update posted | Jun 4, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: